Crotedumab

Crotedumab (REGN1193) (INN) is a humanized monoclonal antibody designed for the treatment of diabetes.^[1][2]

Crotedumab

Monoclonal antibody
Type	Whole antibody
Source	Human
Target	GCGR
Clinical data
Other names	REGN1193
ATC code	none
Identifiers
CAS Number	1452387-69-7
ChemSpider	none
UNII	4JQ68PW6XF
KEGG	D11230
Chemical and physical data
Formula	C6518H10044N1732O2052S46
Molar mass	146976.88 g·mol−1

This drug was developed by Regeneron Pharmaceuticals but is no longer under development.^[3]